Loading...
XNYSVAPO
Market cap13mUSD
Sep 19, Last price  
2.17USD
Name

Vapotherm Inc

Chart & Performance

D1W1MN
XNYS:VAPO chart
P/E
P/S
0.20
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
75.45%
Rev. gr., 5y
10.14%
Revenues
69m
+2.80%
30,122,00035,597,00042,377,00048,104,000125,733,000113,292,00066,801,00068,669,000
Net income
-58m
L-48.62%
-23,072,000-31,005,000-42,468,000-51,059,000-56,213,000-59,800,000-113,259,000-58,193,000
CFO
-24m
L-69.72%
-25,371,000-29,246,000-40,520,000-39,662,000-39,468,000-55,371,000-80,157,000-24,272,000
Earnings
Feb 20, 2025

Profile

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
IPO date
Nov 14, 2018
Employees
261
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
68,669
2.80%
66,801
-41.04%
113,292
-9.89%
Cost of revenue
106,411
144,247
170,029
Unusual Expense (Income)
NOPBT
(37,742)
(77,446)
(56,737)
NOPBT Margin
Operating Taxes
126
11
(76)
Tax Rate
NOPAT
(37,868)
(77,457)
(56,661)
Net income
(58,193)
-48.62%
(113,259)
89.40%
(59,800)
6.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
20,943
1,292
BB yield
-346.88%
-1.79%
Debt
Debt current
2,414
2,313
6,608
Long-term debt
115,311
105,190
46,836
Deferred revenue
Other long-term liabilities
3,878
7,827
10,521
Net debt
108,000
91,765
(3,627)
Cash flow
Cash from operating activities
(24,272)
(80,157)
(55,371)
CAPEX
(2,994)
(11,610)
(5,895)
Cash from investing activities
(2,994)
(11,610)
(7,199)
Cash from financing activities
21,038
51,324
4,370
FCF
(26,604)
(91,495)
(65,146)
Balance
Cash
9,725
15,738
57,071
Long term investments
Excess cash
6,292
12,398
51,406
Stockholders' equity
(548,098)
(490,130)
(376,691)
Invested Capital
609,034
567,752
498,763
ROIC
ROCE
EV
Common stock shares outstanding
6,037
3,342
3,242
Price
1.00
-95.37%
21.60
-86.96%
165.68
-22.90%
Market cap
6,037
-91.64%
72,179
-86.56%
537,155
-16.04%
EV
114,037
163,944
533,528
EBITDA
(32,765)
(72,266)
(51,089)
EV/EBITDA
Interest
18,733
11,643
2,595
Interest/NOPBT